Botulinum toxin type A

BOTOX® Cosmetic receives FDA approval for temporary improvement in appearance of moderate to severe vertical bands connecting jaw and neck (platysma bands) in adults, expanding its indications to forehead lines, frown lines, crow's feet lines, and now platysma bands.

Allergan Aesthetics announces FDA approval of Botox Cosmetic for temporary improvement in moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults, expanding its aesthetic indications beyond the face.

Evolus, Inc. granted 10,251 stock options and 31,049 RSUs to 16 new non-executive employees, and 40,286 stock options and 28,213 RSUs to Senior VP Umberto La Magna, all under the 2023 Inducement Incentive Plan, with a vesting commencement date of October 7, 2024.

Predicting dementia in primary care for 60-79 year olds should include age, history of stroke or epilepsy, gait problems, anticholinergic burden, use of SSRIs, receipt of social services, third-party involvement in consultations, and high missed primary care appointments. For 80-89 year olds, similar factors apply but with weaker associations. S100β levels 24 hours post-IVT are independently associated with hemorrhagic transformation, infarct volume, and prognosis in stroke patients. DaxibotulinumtoxinA-lanm 500U showed the greatest reduction in MAS scores in patients with spasticity following stroke or traumatic brain injury. Double-dose ESWT to the gastrocnemius and soleus showed greater improvements in post-stroke ankle plantar flexor spasticity. Just-in-time adherence support systems in gamified cognitive training should be applied based on key performance indicators like highest level achieved, total game sessions played, and overall gameplay proportion.

ION464 (BIIB101) in MSA patients shows safety and tolerability; ELATE trial evaluates onabotulinumtoxinA for upper limb essential tremor; Mediterranean-ketogenic diet study in PD patients reveals barriers to ketogenic interventions.

AEON Biopharma announced positive FDA Biosimilar Advisory Meeting outcome for ABP-450 as a BOTOX® biosimilar, aligning on the 351(k) regulatory pathway. Comparative analytical studies start Q4 2024, with a BPD Type 2 meeting planned for 2025. AEON aims to bring prabotulinumtoxinA to the U.S. market for all BOTOX's approved and future therapeutic indications under a single approval, anticipating a Phase 3 program to compare ABP-450 with BOTOX®.

Allergan Aesthetics launches BOTOX® Cosmetic for masseter muscle prominence (MMP) in China, supported by clinical trials showing effectiveness and safety. Plans include expanding MMP treatment to other global markets.

Xeomin, first approved in 2011 for frown lines, now also treats forehead and crow's feet lines. It's the first FDA-approved neurotoxin for simultaneous treatment of upper facial lines, containing only essential ingredients. The new indication is based on clinical studies showing its efficacy and safety, with high patient satisfaction and continued efficacy over multiple treatment cycles.